San Diego's Arena Pharmaceuticals Inc. (Nasdaq: ARNA) was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the U.S. Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2).
Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting a Phase 1 single-ascending dose trial.
"This patent provides us further confidence that APD371 can be exclusive to Arena until at least 2030," said Jack Lief, Arena's president and CEO.
Arena owns patents and pending patent applications covering compositions of matter for APD371 and related compounds, as well as methods of treatment utilizing APD371 and related compounds. Patent applications for APD371 have been filed in 23 jurisdictions, including the United States, Europe, Japan and China. The jurisdictions where patent applications have been filed are estimated to have accounted for more than 95 percent of global pharmaceutical sales in 2011.
APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate Arena is exploring for several potential indications, including chronic pain. This compound is designed to be highly selective to provide pain relief without psychotropic effects and without the potential for dependence or abuse. Preclinical efficacy with APD371 has been shown in animal models of pain.
6166 Nancy Ridge Drive
San Diego, CA 92121